Cerus vs MiMedx
CERS and MDXG side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CERS and MDXG compare
Cerus and MiMedx are about the same size, with market caps of $427M and $484M.
Cerus keeps more of each dollar of sales as profit, with a net margin of −2.9% compared with −6.3% at MiMedx.
MiMedx scores higher on the StockData Score (12 against 6 for Cerus), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CERS | MDXG |
|---|---|---|
| Size and price | ||
| Market cap | $427M | $484M |
| Share price | $2.12 | $3.32 |
| Change, 1 year | 32.5% | −56.9% |
| Change, 5 years | −70.6% | −57.1% |
| Beta (5Y) | 1.72 | 0.98 |
| Employees | 275 | 808 |
| StockData Score | ||
| Total score | 6 | 12 (better) |
| Valuation score | 2 | 3 (better) |
| Growth score | 0 | 1 (better) |
| Performance score | 3 (better) | 2 |
| Health score | 1 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 1.7× | 1.6× (better) |
| P/B | 5.6× | 2.3× (better) |
| P/FCF | 865× | – |
| FCF yield | 0.12% | – |
| Fair value | $2.72 | $4.92 |
| Margin of safety | 22.1% | 32.5% (better) |
| Growth | ||
| Revenue growth (TTM) | – | −22.8% |
| Revenue growth, 5Y average | 15.4% (better) | 11.0% |
| Net income growth (TTM) | – | −147% |
| EPS growth (TTM) | – | −148% |
| Profitability | ||
| Gross margin | – | 77.3% |
| Operating margin | −0.97% (better) | −8.3% |
| Net margin | −2.9% (better) | −6.3% |
| FCF margin | 0.19% | – |
| Return on equity | −10.7% | −8.5% (better) |
| Return on invested capital | −966% | −19.3% (better) |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Interest coverage | −0.4× | – |
| Current ratio | 1.96 | 4.35 (better) |
| Altman Z-score | −3.78 | 6.52 (better) |
| Piotroski F-score | 5 | 6 (better) |
| Dividends and buybacks | ||
| Buyback yield | 0.01% | – |
| Shareholder yield | 0.01% (better) | 0.00% |
| Ownership | ||
| Held by institutions | 74.8% | 79.9% |
| Held by insiders | 6.0% | 2.9% |
| Insider net buying, 12 months | −$3.2M | $0 (better) |
| Short interest, % of float | 7.7% | 6.3% |
Go deeper
- CERS stock overview
- CERS income statement
- CERS valuation and score
- MDXG stock overview
- MDXG income statement
- MDXG valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.